<VariationArchive VariationID="1070469" VariationName="NM_000546.6(TP53):c.205del (p.Ala69fs)" VariationType="Deletion" Accession="VCV001070469" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-08" DateCreated="2021-05-10" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1064430" VariationID="1070469">
      <GeneList>
        <Gene Symbol="TP53" FullName="tumor protein p53" GeneID="7157" HGNC_ID="HGNC:11998" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7668421" stop="7687490" display_start="7668421" display_stop="7687490" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7571719" stop="7590867" display_start="7571719" display_stop="7590867" Strand="-" />
          </Location>
          <OMIM>191170</OMIM>
          <Haploinsufficiency last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000546.6(TP53):c.205del (p.Ala69fs)</Name>
      <CanonicalSPDI>NC_000017.11:7676163:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7676164" stop="7676164" display_start="7676164" display_stop="7676164" variantLength="1" positionVCF="7676163" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7579482" stop="7579482" display_start="7579482" display_stop="7579482" variantLength="1" positionVCF="7579481" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>A30fs</ProteinChange>
      <ProteinChange>A69fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.7579483del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.7579483del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.7676165del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.7676165del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017013.2" sequenceAccession="NG_017013" sequenceVersion="2" change="g.16387del">
            <Expression>NG_017013.2:g.16387del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126113.3" sequenceAccession="NM_001126113" sequenceVersion="3" change="c.205del">
            <Expression>NM_001126113.3:c.205del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119585.1" sequenceAccession="NP_001119585" sequenceVersion="1" change="p.Ala69fs">
            <Expression>NP_001119585.1:p.Ala69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126114.3" sequenceAccession="NM_001126114" sequenceVersion="3" change="c.205del">
            <Expression>NM_001126114.3:c.205del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119586.1" sequenceAccession="NP_001119586" sequenceVersion="1" change="p.Ala69fs">
            <Expression>NP_001119586.1:p.Ala69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126118.2" sequenceAccession="NM_001126118" sequenceVersion="2" change="c.88del">
            <Expression>NM_001126118.2:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119590.1" sequenceAccession="NP_001119590" sequenceVersion="1" change="p.Ala30fs">
            <Expression>NP_001119590.1:p.Ala30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276695.3" sequenceAccession="NM_001276695" sequenceVersion="3" change="c.88del">
            <Expression>NM_001276695.3:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263624.1" sequenceAccession="NP_001263624" sequenceVersion="1" change="p.Ala30fs">
            <Expression>NP_001263624.1:p.Ala30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276696.3" sequenceAccession="NM_001276696" sequenceVersion="3" change="c.88del">
            <Expression>NM_001276696.3:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263625.1" sequenceAccession="NP_001263625" sequenceVersion="1" change="p.Ala30fs">
            <Expression>NP_001263625.1:p.Ala30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276760.3" sequenceAccession="NM_001276760" sequenceVersion="3" change="c.88del">
            <Expression>NM_001276760.3:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263689.1" sequenceAccession="NP_001263689" sequenceVersion="1" change="p.Ala30fs">
            <Expression>NP_001263689.1:p.Ala30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276761.3" sequenceAccession="NM_001276761" sequenceVersion="3" change="c.88del">
            <Expression>NM_001276761.3:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263690.1" sequenceAccession="NP_001263690" sequenceVersion="1" change="p.Ala30fs">
            <Expression>NP_001263690.1:p.Ala30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_321" sequenceAccession="LRG_321">
            <Expression>LRG_321:g.16387del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000546.6" sequenceAccession="NM_000546" sequenceVersion="6" change="c.205del" MANESelect="true">
            <Expression>NM_000546.6:c.205del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000537.3" sequenceAccession="NP_000537" sequenceVersion="3" change="p.Ala69fs">
            <Expression>NP_000537.3:p.Ala69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126112.3" sequenceAccession="NM_001126112" sequenceVersion="3" change="c.205del">
            <Expression>NM_001126112.3:c.205del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119584.1" sequenceAccession="NP_001119584" sequenceVersion="1" change="p.Ala69fs">
            <Expression>NP_001119584.1:p.Ala69fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2151041861" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000546.6(TP53):c.205del (p.Ala69fs) AND Li-Fraumeni syndrome" Accession="RCV001382613" Version="4">
        <ClassifiedConditionList TraitSetID="2589">
          <ClassifiedCondition DB="MedGen" ID="C0085390">Li-Fraumeni syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-09-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.205del (p.Ala69fs) AND Li-Fraumeni syndrome 1" Accession="RCV004037657" Version="1">
        <ClassifiedConditionList TraitSetID="3343">
          <ClassifiedCondition DB="MedGen" ID="C1835398">Li-Fraumeni syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-12" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-05-10" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20522432</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10539" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome</ElementValue>
                <XRef ID="MONDO:0018875" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
                <XRef ID="428850001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sarcoma family syndrome of Li and Fraumeni</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6902" />
                <XRef ID="6902" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="C0085390" DB="MedGen" />
              <XRef ID="MONDO:0018875" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3343" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5406" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome 1</ElementValue>
                <XRef ID="C538639" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
                <XRef Type="MIM" ID="151623" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">LFS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 1995">
                <ID Source="pmc">1801355</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 2015">
                <ID Source="PubMed">26140447</ID>
                <ID Source="pmc">4570999</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="553989" DB="Gene" />
              <XRef ID="C1835398" DB="MedGen" />
              <XRef Type="MIM" ID="151623" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3107071" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="11742854|MedGen:C0085390" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001581454" DateUpdated="2024-02-28" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20522432</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432). This variant has not been reported in the literature in individuals with TP53-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ala69Leufs*54) in the TP53 gene. It is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.7579482del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085390" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9142052" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="101388353|OMIM:151623" />
        <ClinVarAccession Accession="SCV004932757" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="17" alternateAllele="G" referenceAllele="GC" start="7579481" stop="7579482" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">101388353</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="151623" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9142052" TraitType="Disease" MappingType="XRef" MappingValue="151623" MappingRef="OMIM">
        <MedGen CUI="C1835398" Name="Li-Fraumeni syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3107071" TraitType="Disease" MappingType="XRef" MappingValue="C0085390" MappingRef="MedGen">
        <MedGen CUI="C0085390" Name="Li-Fraumeni syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

